Amphotericin B Liposome For Injection Drug Interactions

No specific interaction studies have been reported with Amphotericin B Liposome for Injection. However, the following drugs are known to interact with amphotericin B and may interact with Amphotericin B Liposome for Injection.
Nephrotoxic medications: Concurrent administration of Amphotericin B Liposome for Injection with other nephrotoxic agents, (for example ciclosporin, aminoglycosides and pentamidine) may enhance the potential for drug-induced renal toxicity in some patients. However, in patients receiving concomitant ciclosporin and/or aminoglycosides, Amphotericin B Liposome for Injection was associated with significantly less nephrotoxicity compared to amphotericin B.
Regular monitoring of renal function is recommended in patients receiving Amphotericin B Liposome for Injection with any nephrotoxic medications.
Corticosteroids, corticotropin (ACTH) and diuretics: Concurrent use of corticosteroids, ACTH and diuretics (loop and thiazide) may potentiate hypokalaemia.
Digitalis glycosides: Amphotericin B Liposome for Injection induced hypokalaemia and may potentiate digitalis toxicity.
Skeletal muscle relaxants: Amphotericin B Liposome for Injection induced hypokalaemia may enhance the curariform effect of skeletal muscle relaxants (e.g. tubocurarine).
Antifungals: Concurrent use with flucytosine may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
Antineoplastic agents: Concurrent use of antineoplastic agents may enhance the potential for renal toxicity, bronchospasm and hypotension. Antineoplastic agents should be given concomitantly with caution.
Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients given amphotericin B (as sodium deoxycholate complex) during or shortly after leukocyte transfusion. It is recommended these infusions are separated by as long a period as possible and pulmonary function should be monitored.